YS Biopharma Co., Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hui Shao
- Full Time Employees
- 773
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building No. 2 Beijing People's Republic of China 102600
- IPO Date
- Aug 5, 2021
- CIK
- 0001946399
- Website
- yishengbio.com
- Similar Companies
- Business
- YS Biopharma Co., Ltd. (NASDAQ: YS), formerly known as YS Biopharma and recently changed to LakeShore Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing next-generation vaccines and therapeutic biologics for infectious diseases and cancer; its commercialized products include the YSJA rabies vaccine; its clinical-stage pipeline features the PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 therapeutic vaccine for cancer, and PIKA YS-HBV-001 for hepatitis B; preclinical candidates target hepatitis B, influenza, shingles, and additional cancer indications using its proprietary PIKA immunomodulating adjuvant technology platform; the company also advances discovery-stage programs for rabies and other therapeutic targets. Founded prior to its 2021 initial public offering through a business combination with Summit Healthcare Acquisition Corp. that provided approximately $36 million in gross proceeds and completed in March 2023, YS Biopharma is headquartered in Beijing, China, with approximately 773 employees and operations principally in China, the United States, Singapore, the United Arab Emirates, and the Philippines. Recent developments include the completion of subject enrollment in the pivotal Phase 3 clinical trial for its PIKA rabies vaccine in 2024; a name change to LakeShore Biopharma announced in May 2024; and in August 2025, the receipt of a revised preliminary non-binding proposal from a consortium comprising Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc.—who collectively own about 52.1% of outstanding shares—to acquire all remaining ordinary shares in an all-cash transaction at $0.86 per share, funded by equity rollover and cash without debt financing conditions.
YS Biopharma Announces Name Change to LakeShore Biopharma
YS Biopharma Announces Results of Extraordinary General Meeting
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance
YS Biopharma Announces Appointment of New Directors
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.
YS Biopharma Announces US$40 Million Private Placement Financing
Shareholders of YS Biopharma Announce an Extraordinary General Meeting
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024